law.justia.com/cases/federal/appellate-courts/cadc/16-5356/16-5356-2018-06-19.html

Jun 19, 2018 ... Therefore, all of the communications were protected by the ... FTC v. Boehringer Ingelheim Pharmaceuticals, Inc., No. 16-5356 (D.C. Cir. 2018).

law.justia.com/cases/federal/district-courts/new-jersey/njdce/3:2015cv05982/323095/388

Dec 7, 2016 ... BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v. HEC PHARM CO. , LTD. et al, No. 3:2015cv05982 - Document 388 (D.N.J. 2016) ...

www.law360.com/cases/59820bc59c43e06ea0000001

Parties, docket activity and news coverage of federal case AbbVie Inc. et al v. Boehringer Ingelheim International GMBH et al, case number 1:17-cv-01065, from ... for modulating protein glycosylation profiles of recombinant protein therapeutics ...

portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A17-cv-01065

Case docket and documents for 1:17-cv-01065 - AbbVie, Inc. et al. v. Boehringer- Ingelheim et al., Delaware District Court, filed at 2017-08-02. ... International GMBH on 8/2/2017; Boehringer Ingelheim Pharmaceuticals, Inc. on 8/2/2017.

www.cadc.uscourts.gov/internet/opinions.nsf/A81BAEEA3D756416852582B100518ADF/$file/16-5356.pdf

Jun 19, 2018 ... Boehringer Ingelheim Pharmaceuticals, Inc. Warren D. ... alleged infringer, rather than the other way around.” FTC v. Actavis, Inc., 570 U.S. 136, 141 (2013). .... All of those communications are protected by the attorney-client ...